An engineered 4-1BBL fusion protein with ''activity-on-demand''
J. C. Mock, M. Stringhini, A. M. Villa, D. Neri
This paper describes an engineered antibody-cytokine fusion protein that activates only upon antigen binding, showing potent anti-tumor activity with reduced toxicity in mouse models.
bioRxiv · Apr 29, 2020Cancer Biology